An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Iveric Bio (NASDAQ: ISEE) is set to release its first quarter 2022 financial and operational results on May 4, 2022. The company's management will hold a live conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. Iveric Bio focuses on developing innovative treatments for retinal diseases. Interested participants can join the call by dialing in or accessing the live webcast through the company's investor relations website.
Positive
Scheduled release of first quarter 2022 financial results on May 4, 2022.
Management will provide a business update and discuss financial outcomes.
Focus on novel treatments for retinal diseases addresses significant unmet medical needs.
Negative
None.
PARSIPPANY, N.J.--(BUSINESS WIRE)--
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
To participate in this conference call, dial 1-888-317-6003 (USA) or 1-412-317-6061 (International), passcode 1313914. A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the Iveric Bio website at www.ivericbio.com. A replay will be available approximately two hours following the live call for two weeks. The replay number is 1-877-344-7529 (USA Toll Free), passcode 9999784.
About Iveric Bio Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.
Forward-looking Statements
Any statements in this press release about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release. Iveric Bio anticipates that subsequent events and developments will cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so.
When will Iveric Bio report its Q1 2022 financial results?
Iveric Bio will report its first quarter 2022 financial results on May 4, 2022.
What time is the Iveric Bio conference call for Q1 2022 results?
The conference call will take place at 8:00 a.m. Eastern Time.
How can I listen to the Iveric Bio earnings call?
You can listen to the earnings call by dialing 1-888-317-6003 for the USA or 1-412-317-6061 for international callers, or via the live webcast on the Iveric Bio website.
What is the focus of Iveric Bio's research?
Iveric Bio is focused on the discovery and development of treatments for retinal diseases.
